Drugs / Huazhi Rougan Granule
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT06202456 | May 2020 → Jun 2022 | — | Shandong New Time Pharmaceutical Co., LTD | Completed | No outcome recorded |
| Phase 4 | NCT06188611 | May 2017 → Nov 2018 | — | Shandong New Time Pharmaceutical Co., LTD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07159412 | Aug 2025 → Aug 2026 overdue | Helicobacter pylori infectious disease, metabolic dysfunction-associated steatohepatitis | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huazhi Rougan Granule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188611 ↗ |
| Route | Oral | “Huazhi Rougan Granule (taken orally three times daily” NCT07159412 ↗ |